A hypoglycemic interaction is any supplement pattern that can additively lower blood glucose alongside antidiabetic medications, especially insulin, sulfonylureas, meglitinides, or medication combinations where low glucose is already a known concern. The platform flags this category because several routinely used supplements have published glucose-lowering signals that can matter in medication-managed diabetes.
Why additive lowering matters
Antidiabetic prescriptions are titrated against a baseline that assumes a typical glycemic background. When a supplement consistently changes fasting or post-meal glucose, the prescriber may need to interpret readings differently during the trial period. The early signs — shakiness, sweating, irritability, hunger, confusion — are easy to miss in users without prior hypoglycemic episodes.
Supplements most commonly flagged
The platform flags pairings with antidiabetic prescriptions for berberine, cinnamon, chromium, gymnema sylvestre, alpha-lipoic acid, and fenugreek. See interaction risk for the tiering logic that determines whether a pair is held, activated with a note, or activated normally.
Why the flag is about variability as much as average effect
A supplement that lowers fasting glucose by a small average margin can still produce a sharp drop in a subset of users on a specific day — after a missed meal, a heavier exercise session, or a recent prescription up-titration. Average effects from trials do not predict the worst-case day for any single user, which is one reason the platform pairs a flag with a self-monitoring note rather than treating the average as the operative number.
Why the flag is conservative
Antidiabetic prescriptions can already require individualized glucose monitoring plans, so the platform treats supplement overlap as a conservative flag rather than as a dose-adjustment prompt. For first-time stack builders on these prescriptions, the pillar overview at building your first supplement stack covers how the prescription field filters candidates before the first shortlist is shown.
What to do when a flag fires
When a flag fires, the app keeps the supplement from activating and records the specific product label, medication class, and overlap reason for clinician review outside the glossary flow.
Limits of the screen
Published trial doses for glucose-lowering supplements vary widely, and over-the-counter products often differ in standardization from the products used in trials. The platform marks low-confidence pairs explicitly so the user can ask a sharper question rather than assume parity with well-studied pairs.
How this appears in Unfair
An antidiabetic prescription in the user profile triggers a screen across glucose-active supplements. Matched supplements are held with a clinician-question template pre-filled on the stack record.
Clinical safety note
Symptom interpretation and glucose-management decisions are outside the scope of a glossary entry or supplement journal.